Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG)

Abraham, J., Coleman, R., Elias, A. et al. (9 more authors) (2018) Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG). Breast Cancer Research and Treatment, 171 (1). pp. 11-20. ISSN 0167-6806

Abstract

Metadata

Authors/Creators:
  • Abraham, J.
  • Coleman, R.
  • Elias, A.
  • Holmes, F.A.
  • Kalinsky, K.
  • Kittaneh, M.
  • Lower, E.
  • Mahtani, R.
  • Terry Mamounas, E.
  • Pegram, M.
  • Vogel, C.
  • Breast Cancer Therapy Expert Group (BCTEG), .
Copyright, Publisher and Additional Information: © The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Keywords: Breast cancer; Hormone receptor positive; CDK Metastatic breast cancer; BCTEG Cyclin-dependent kinase; Endocrine therapy
Dates:
  • Published (online): 4 May 2018
  • Published: August 2018
Institution: The University of Sheffield
Depositing User: Symplectic Sheffield
Date Deposited: 07 Aug 2018 11:45
Last Modified: 07 Aug 2018 11:45
Published Version: https://doi.org/10.1007/s10549-018-4783-1
Status: Published
Publisher: Springer
Refereed: Yes
Identification Number: https://doi.org/10.1007/s10549-018-4783-1

Share / Export

Statistics